QR-Code

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report

Background: Although most phase III pivotal trials have set the duration of immune checkpoint blockers (ICB) for advanced NSCLC at 2 years, the criteria for safely discontinuing ICB remain undefined. Growing evidence links ICB efficacy to gut microbiota, positioning gut microbial taxonomic profiling...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Adele Bonato, MD, Claudia Parisi, MD, Priscilla Cascetta, MD, Anna Reni, MD, May-Lucie Meyer, MD, Mariona Riudavets, MD, PhD, David Planchard, MD, PhD, Benjamin Besse, MD, PhD, Jordi Remon, MD, Francesco Facchinetti, MD, PhD, Lorenzo Belluomini, MD, PhD, Lisa Derosa, MD, PhD, Fabrice Barlesi, MD, PhD
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2026-01-01
Schriftenreihe:JTO Clinical and Research Reports
Schlagworte:
NSCLC
Immunotherapy
Duration
(Dis)continuation
Gut microbiome
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2666364325001468
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge